New formulations of drugs in epilepsy

Expert Opinion on Pharmacotherapy

Volumn 1, Issue 1, 1999, Pages 49-60

  Wheless, James W ^a   Venkataraman, Vijay ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Anti epileptic drugs; Epilepsy; Extended release carbamazepine; Fosphenytoin; Intravenous valproate; Lamotrigine; Rectal diazepam; Topiramate

Indexed keywords

ANTICONVULSIVE AGENT;

CLINICAL TRIAL; DELAYED RELEASE FORMULATION; EPILEPSY; HUMAN; REVIEW;

ANTICONVULSANTS; CLINICAL TRIALS; DELAYED-ACTION PREPARATIONS; EPILEPSY; HUMANS;

EID: 0033224355     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.1.1.49     Document Type: Article

References (68)

1. SMITH DB, MATTSON RH, CRAMER JA, COLLINS JF, NOVELLY KA, CRAFT B: Results of a nationwide Veterans Administration Cooperative Study comparing the efficacy and toxicity of carbamazepine, phenobarbital, phenytoin, and primidone. Epilepsia (1987) 28(Suppl. 3):S50-58.
2. YUKAWA E: Optimization of antiepilcptic drug therapy. Clin. Pharmacokln. (1996) 31:120-130.
3. POST KM, TRIMULE MR, PIPPENGER CE: Clinical Use of Anticonvtilsanls in Psychiatric Disorders. Demos Publishers, New York City, USA (1989).
4. BARRY JJ: Psychiatric uses for anticonvulsants.In: Merritt-Putnam Lectures, CME Monograph: Update on Epilepsy Management and Emerging Uses of Anti-epileptic Drugs. American Epilepsy Society, West Hartford. CN, USA (1999):89-104.
5. MORSELLI PL: In: Anti-Fflleptlc Dmgs (4th Edition). Levy RH, Mattson RH, Meldrum BS (Eds.), Raven Press, New York. USA (1995) 515.
6. RIVA R, ALBANI F, AMBROSETTO G et al.: Diurnal fluctuations in free and total steady-state plasma levels of carbamazcpinc and correlation with intermittent side effects. Epilepsia. (1984) 25(4):476-481.
7. CRAMER JA, MATTSON RH, PREVEY ML, SCHEYER RD, OUELLETE VL: How often is medication taken as prescribed? JAMA (1989) 26l(22):3273-3277.
8. Data on file. Shire Richwood, Inc. Florence, KY 41042. (Tel.: +1 800 536 7878).
9. CLOYD JC, KRIEL RL, JONES-SAETE CM et al. Comparison of sprinkle t-ersus syrup formulations of valproate for bioavailability, tolerance, and preference. J. Pediatr. (1992) 120:634-638.
10. GARNETT WR, LEVY B, MCLEAN AM et al.: Pharmacokinetic evaluation of twice-daily extended-release carbamazcpinc (CBZ) and four-timcs-daily immediate-release CBZ in patients with epilepsy. Efnlcpsia (1998) 39(3);274-279.
11. MIRZA WU, RAK IW, THADANI VM et al.: Six-month evaluation of Carbatrol (extended-release carbamazcpinc) in complex partial seizures. Neurology: (1998) 51:1727-1729. • Prospective evaluation of the efficacy and pharmacokinetics of CBTL.
12. THEEUWES F, SWANSON DR, GUITTARD G, AYER A, KHANNA S: Osmotic delivery systems for the adrenoccptor antagonists mctoprolol and oxprcnolol: design and evaluation of systems for once-daily administration. Br.J. Clin. Pharmacol. (1985) 19:69S-76S.
13. THE TEGRETOL OROS OSMOTIC RELEASE DELIVERY SYSTEM STUDY GROUP: Double-blind crossover comparison of Tcgrctol-XR and Tegretol in patients with epilepsy. Neurology. (1995) 45:1703-1707. • Prospective evaluation of the efficacy and pharmacokinetics of TXR.
14. WILDING IR, DAVIS SS, HARDY JG et al.: Relationship between systemic drug absorption and gastrointestinal transit after the simultaneous oral administration of carbamazcpinc as a controlled-releasc system and as a suspension of 15N-labcllcd drug to healthy volunteers. Br.J. Clin. Pharmacol. (1991) 32(5) 573-579. Best documentation of effect of gastrointestinal transit time on efficacy of sustained release medication.
15. MCKEE PJ, BLACKLAWJ, BUTLER E, GILLHAM RA, BRODIE MJ: Monothcrapy with conventional and controlledreleasc carbamazcpinc: a double-blind, double-dummy comparison in epileptic patients. Br. J. Clin, Pharmacol. (1990 32:99-104.
16. STEVENS RE, LIMSAKUN T, EVANS G, MASON DH: Controlled, multidose, pliarmacokinctic evaluation of two extended-release carbamazcpinc formulations (Carbatrol and Tegretol-XR). J. Pharmacol. Sci. 87(12):1531-1534. • Good pharmacokinetic comparison of these two drugs.
17. FRANK LM, ENLOW T, HOLMES G et al.: Lamictal (lamotriginc) monothcrapy for typical absence seizures in children. Eptlejtsta (1999) 10(7.):973-979. • Documents the efficacy of lamotrigine in absence seizures.
18. MIKATI MA, HOLMES GL: Lamotrigine in absence and primary generalized epilepsies. J. Child Neurol. (1997) 12(SuppI. 1):S29-S37.
19. MOTTE J, TREVATHAN E, AUVIDSSON JF, BARRERA MN, MULLENS EL, MANASCO P: Lamotrigine for generalized seizures associated with the Lcnnox-Gastaut syndrome. Lamictal Lcnnox-Gastaut Study Group. New Engl.J. Med. (1997) 337(25):1807-1812. • Establishes Lamictal's efficacy in this seizure syndrome.
20. DULAC O, KAMINSKA A: Use of lamotrigine in LennoxGastaut and related epilepsy syndromes. J. Child Neurol. (1997) 12(Suppl. 1):S23-S28.
21. SCHLUMBERGERE, CHAVEZ F, PALACIOS L, REY E, PAJOB N, DULAC O: Lamotrigine in treatment of 120 children with epilepsy. Epilepsia (1994) 35(2):359-367.
22. DOOSE DR, WALKER SA, SCOTT W et al.: The comparative bioavailability of topiramatc from two invcstigational pédiatrie sprinkle formulations relative to a Tablet formulation. Epilepsia.(1996) 37(Suppl. 5):112.
23. DOOSE DR, WALKER SA, BALDASSARRE J: The effect of food on the oral bioavailability of topiramatc from an invcstigational pacdiatric sprinkle formulation. Epilepsia (1997) 38(Suppl. 3):147.
24. SACHDEO RC, GLAUSER TA, RITTER F, REIFE R, LIM P, PLEDGER G: A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology. (1999) 52(9):1882-1887. • Documents topiramates efficacy in this epilepsy syndrome.
25. ELTERMAN RD, GLAUSER TA, WYLLIE E, REIFE R, WU SC, PLEDGER G: A double-blind, randomized trial of topiramatc as adjunctivc therapy for partial onset seizures in children. Topiramatc YP Study Group. Neurology. (1999) 52(7):1338-1341.
26. BITON V, MONTOURIS GD, RITTER F et al.: A randomized, placebo-controlled study of topiramatc in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology. (1999) 52(7):1330-1337.
27. GLAUSER TA, CLARK PO, STRAWSBURG R: A pilot study of topiramatc in the treatment of infantile spasms. Epilcpsia (1998) 39(12):1324-1328.
28. GLAUSER TA: Topiramatc use in pédiatrie patients. Can.J. Xeitrol. Sci. (1998) 25(3):S8-S12. • Good review of topiramate responsive seizure types.
29. HAUSER WA, HESDOKFFER DC: Incidence and prevalence. In: Epilepsy: Frequency, Causes and Consequences. Hauser WA, Hesdorffer DC (Eds.), Demos Publications, New York, USA (1990):1-51.
30. LOWENSTEIN DH: Seizures and status epilepticus. In: Current Practice of Emergency Medicine (2nd Edition). Callahnm ML (Ed.), BC Decker, Philadelphia, USA (1990:307-313.
31. CRANFORD RE, LEPPIK IE, PATRICK IS etal: Intravenous phcnytoin in acute treatment of seizures. Neurology (1979) 29:1476-1479.
32. WHELESS, JW: Treatment of acute seizures and status epilepticus in children. Resident Staff Physician (1999) 45(Suppl. 10). (In Press). Good review of current treatment.
33. BROWNE TR, KUGLER AR. ELDON MA: Pharmacology and pharmacokinetics of fosphenytoin. Neurology. (1996)46(Suppl. 1):S3-S7.
34. SMITH RD, BROWN BS, MAHER RW, MATIER WL: Pharmacology of ACC-9653 Cphenytoin prodrug). Epilepsia. (1989) 30(Suppl. 2):S15-S21.
35. AWEEKA FT, GOTTWALD MD, GAMHERTOGLIO JG et al.: Pharmacokinetics of fosphenytoin in patients with hepatic or renal disease. Epilepsia (1999) 40(6):777-782.
36. FISCHER JH, CWIK MJ, LUER MS, SIBLEY CB, DEYO KL: Stability of fosphenytoin sodium with intravenous solutions in glass bottles, polyvinyl chloride bags, and polypropylene syringes. Ann. Pharmacother. (1997) 31:533-539.
37. WHELESS JW: Pédiatrie use of intravenous and intramuscular phenytoin: lessons learned. J. Child Neurol. (1998) 13(Suppl. 1):S11-S14. • Good review of this drug's historical use.
38. JAMERSON BD, DUKES GE, BROUWER KLR, DONN KH, MESSENHEIMER JA, POWELL JR: Venous irritation related to intravenous administration of phcnytoin versus fosphenytoin. Pharmacotherapy (1994) 14(1):47-52.
39. UTHMAN BM, WILDER BJ, RAMSAY RE: Intramuscular use of fosphenytoin: an overview. Neurology (1996) 46(Suppl. 1):S24-S28.
40. FIERRO LS, SAVULICH DH, BENEZRA DA: Safety of fosphenytoin sodium. Am.J. Health-Syst. Pharm. (1996) 53:2707-2712.
41. JOHNSON NE, DOYLE JJ: A stcpwise approach to performing a preliminary pharmacocconomic analysis: Focus on fosphenytoin. Pbarm. Ther. (1996):6ll-628.
42. MARCHETTI A, MAGAR R, FISCHER J, SLOAN E, FISCHER P: A pharmacoeconomic evaluation of intravenous fosphenytoin (Cerebyx) versus intravenous phcnytoin (Dilantin) in hospital emergency departments. Clin. Ther. (1996) 18(5):953-966.
43. O'BRIEN TJ, CASCINO GD, SO EL, HANNA DR: Incidence and clinical consequences of the purple glove syndrome in patients receiving intravenous phenytoin. Neurology (1998) 51:1034-1039.
44. MATTSON RH: Parenteral antiepileptic/anticonvulsant drugs. Neurology (1996) 46(Suppl. 1):S8-S13.
45. RAMSAY RE, DETOLEDO J: Intravenous administration of fosphenytoin: options for the management of seizures. Neurology (1996) 46(Suppl. 1):S17-S19.
46. DULAC O, ARTHUIS M: Open frials with valproate in epilepsy. Epllepsia (1984) 25(Suppl. 1):523-531.
47. HOLLE LM, GIDA BE, COLLINS DM: Valproate in status epilepticus. Ann. Pharmacother (1995) 29:10-42-1044.
48. MARLOW N, COOKE RWI: Intravenous sodium valproate in the neonatal intensive care unit. Fourth International Symposium on Sodium Valproate and Efnlepsy. Royal Soc. Meet. Intern. Congr. Symp. Sei: (1989) 152:208-210.
49. PRICE DJ: Intravenous valproate: experience in neurosurgery. Fourth International Symposium on Sodium Valproate and Epilepsy. Royal Soc. Mcd. Intern. Congr. Symp. Ser. (1989) 152:197-203.
50. DEVINSKY O, LEPPIK I, WILLMORE LJ et al.: Safety of intravenous valproate. Ann. Nenrol. (1995) 38:670-674. Establishes general safety of this treatment.
51. RAMSAY RE, UTHMAN B, LEPPIK IE etal.: The tolerability and safety of valproate sodium injection given as an intravenous infusion.J. Epilepsy (1997) 10:187-193.
52. WHELESS JW, VENKATARAMAN V: Safety of high intravenous valproate loading doses in epilepsy patients.J.Epilepsy W(1998) 11(6):319-324. Establishes iv. loading dose-of valproate.
53. NARITOKU DK, MUEED S: Intravenous loading of valproate for epilepsy, clin. Neuropharmacol. (1999) 22(2):102-106.
54. VENKATARAMAN V, WHELESS JW: Safety of rapid intravenous infusion of valproate loading doses in epilepsy patients. Epilepsy Res. (1999) 35:147-153.
55. HOVINGA CA, CHICELLA MF, ROSE DF, EADES SK, DALTON JT, PHELPS SJ: Use of intravenous valproate in three pédiatrie patients with nonconvulsivc or convulsive status epilepticus. Ann. Phartnacother. (1999) 33:579-584.
56. Treatment of convulsive status epilepticus: Recommendations of the Epilepsy Foundation of America's Group on Status Epilepticus. JAMA (1993) 270:854-859.
57. SCHMIDT D: Bcnzodiazcpincs: diazepam. In: Anti-Epileptic Drugs (4tb Edition). Levy RH, Mattson RH, Meldrum BS (Eds.), Raven Press, New York, USA (1995):705-724.
58. DHILLON S, OXLEY J, RICHENS A: Unavailability of diazcpam after intravenous, oral and rectal administration in adult epileptic patients. Br. J. Clin. Phannacal. (1982) 13:427-432.
59. MOOLEANR F, BARKER S, VISSER J, AND HUIZINGA T: Biopharmaccutics of rectal administration of drugs in man IX. Comparative biopharmaceutics of diazcpam after single rectal, oral. Intramuscular and intravenous administration in man. intem.J. Pharmacal. (1980); 5:127-137.
60. GARRATTINI S, MARCUCCI F, MORSELLI PL, MUSSINI E: The significance of measuring blood levels of benzodiazepines. In: Biological Effects ofDnigs in Relation to iheir Plasma Concentrations. Davies, Prichaid (Eds.), MacMillnn. London. UK (1973):211-225.
61. FRANZONI E, CARBONI C, LAMBERTINI A: Rectal dlazepam: a clinical and EEG study after a single dose in children. Epilepsia (1983) 24:35-41.
62. MILLIGAN N, DHILLON S, OXLEY J, RICHENS A: Absorption of diazcpam from the rectum and its effect on interictal spikes in the EEG. Epilepsia ( 1982 ) 23:323-331.
63. DIECKMANN RA: Rectal diazepam for prehospital pediatrie status cpilepticus. Ann. Emergency.Med. (1994) 23:216-224.
64. MILLIGAN N, DHILLON SO, RICHENS A, OXLEY J: Rectal diazcpam in the treatment of absence status: a pharmacodynamic study.J. Neurol. Neurosurg. Psychial. (1981) 44:914-917.
65. REMY C, JOURDIL N, VILLEMAIN D, FAVEL P, GENTON P: Intrarectal diazcpam in epileptic adults. Epilepsia (1992) 33(2):353-358.
66. MITCHELL WG: Status cpilcpticus and acute repetitive seizures in children, adolescents, and young adults: etiology, outcome and treatment. Epilepsia. (1996) 37(Suppl. 1):S74-S80.
67. FRITZ E, DREIFUSS N, ROSMAN P, CLOYD JC et al. A comparison of rectal diazepam gel and placebo for acute repetitive seizures. New Engl. J. Med. (1998) 338(26):1869-1875. • Document safety and efficacy of out of hospital seizure treatment.
68. CEREGHINO JJ, MITCHELL WG, MURPHY J, KRIEL RL, ROSENFELD WE, TREVATHAN E: Treating repetitive seizures with a rectal diazcpam formulation: A randomized study. The North American Diastat Study Group. Neurology (1998); 51(5):1274-1282.